SEC Filing Summary: AmerisourceBergen Corporation (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on November 6, 2015. The report details the completion of a strategic acquisition announced previously on October 7, 2015.
Key Financial Metrics
- Transaction Value: The Company paid a purchase price of $2.575 billion in cash.
- Transaction Structure: The acquisition was executed on a cash-free, debt-free basis, subject to certain adjustments.
- Financial Performance: This filing does not provide specific revenue, profit, cash flow, margin, or liquidity metrics for the Company or the acquired entity.
Material Changes
On November 6, 2015, AmerisourceBergen completed the acquisition of PharMEDium Healthcare Holdings, Inc. ("PharMEDium"), a portfolio company of Clayton, Dubilier & Rice. Upon completion, PharMEDium became a wholly owned subsidiary of AmerisourceBergen.
Outlook, Risks, and Management Commentary
The filing confirms the successful closing of the Merger Agreement dated October 5, 2015. A press release announcing the completion was issued on the same date. The text does not contain specific forward-looking guidance, risk factors, or management commentary beyond the confirmation of the transaction's closure and the reference to the full Merger Agreement for complete terms.
Key Facts for Investor Verification
- Verify the final purchase price adjustments, as the $2.575 billion figure is subject to certain adjustments.
- Review the full text of the Merger Agreement (Exhibit 2.1) for detailed terms, covenants, and conditions.
- Confirm the integration timeline and expected synergies in subsequent filings or the referenced press release (Exhibit 99.1).
- Assess the impact of the $2.575 billion cash outlay on the Company's liquidity and debt capacity in the next quarterly report.